HiringGrowing
65/100
1 relevant signal
B
Life-sciences software · Paris, France
Biolevate
Current work outlook
Biolevate develops AI automation for scientific and regulatory workflows in life sciences.
Updated September 22, 2026 · Evidence from public sources
Flags outlook71/ 100Positive
1 verified signal in this assessment
Why this score
Built from company events, not anonymous ratings.
The recent evidence is constructive, but the specific role and team still matter. The score weighs signal recency and source confidence. It is a decision aid—not a verdict on culture or a specific team.
StabilityNot enough data
We need a relevant verified event before scoring this dimension.
Financial healthNot enough data
We need a relevant verified event before scoring this dimension.
InnovationSelective
62/100
1 relevant signal
What moved the outlook
Company timeline
What changed—and why it matters
Read events in order and look for repeated momentum or recurring risk.
Filter in all signals ↗Biolevate raises €30 million and opens a Boston office
Biolevate has raised a €30 million Series A co-led by RAISE France and Orange Ventures and is opening a Boston office as it expands into the United States. The company reports more than a dozen enterprise customers in production and says annual recurring revenue increased twentyfold over the past year.
Employee impact
Read full analysis →The financing and new office create a concrete international-growth signal for enterprise AI, scientific software, regulated workflows, implementation and US commercial roles. Candidates should still verify the size of the Boston build-out, customer concentration and whether reported revenue growth comes from repeatable production contracts.